Roth Capital Maintains Buy On Shares Of NeoGenomics, $7 PT
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on NeoGenomics Inc. (NASDAQ:NEO) with a price target of $7.00.
Chattopadhyay said, “NeoGenomics adds two novel molecular tests to predict acquired resistance and susceptibility to BTK inhibitor (Ibrutinib). While resistance to Ibrutinib has been detected in a few patients, Ibrutinib’s clinical use is expanding rapidly (at least 12 ongoing phase 3 studies, both as single agent and in combination). Hence, we anticipate robust interest especially from bio-pharma clients based on NEO’s increased focus in this segment.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -9.0% and a 43.5% success rate. Chattopadhyay has a 13.2% average return when recommending NEO, and is ranked #3246 out of 3343 analysts.